MDxHealth SA (MDXH)

NASDAQ · Healthcare Services · Services-Medical Laboratories

Price
$0.58
Day
-3.88%

Close 2026-09-24.

The company

A. History and Development of the Company We were incorporated on January 10, 2003 as a company with limited liability ( naamloze vennootschap/société anonyme ) incorporated and operating under the laws of Belgium. We are registered with the legal entities register (Liège) under enterprise number 0479.292.440. We were publicly listed on Euronext Brussels in June 2006 and we had ADSs listed on the Nasdaq Capital Market in November 2021. In November 2023, we completed a share consolidation of our ordinary shares by means of a 1-for-10 reverse split, such that following the share consolidation each ADS represented one ordinary share (instead of 10 ordinary shares previously). Overview We are a commercial-stage precision diagnostics company providing non-invasive, clinically actionable and cost-effective urologic solutions to improve patient care. Our core menu of testing solutions, Confirm mdx for Prostate Cancer (“Confirm mdx”), Genomic Prostate Score (“GPS mdx”), and ExoDx Prostate Test (“Exo mdx”), which we recently added through the acquisition of Exosome Diagnostics, provide personalized DNA and RNA insights to both physicians and patients navigating the complexities of urologic disease and treatment options. Each of our cutting-edge molecular diagnostic technologies provides personalized genomic results enabling tailored approaches that enhance patient well-being while minimizing the need for invasive and unnecessary treatments and procedures.

From Item 1: A. History and Development of the Company · Overview.

Institutional holders

Largest positions reported on Form 13F for the quarter ended 2026-06-30, by value.

Insider trades

Open-market buys and sales filed on Form 4, newest first. Grants, option exercises and tax withholding are left out.

Recent filings